Skip to main content

Table 2 Secondary efficacy endpoints in female subjects treated long-term with C1-INH (SC)

From: Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial

 

All female subjects (n = 76)

Females of childbearing age (n = 42)

Overall study population (N = 126)18

Response (≥ 50% reduction in attacks)

91% (69/76)

90% (38/42)

93% (113/122)

< 1 attack/4 weeks

82% (62/76)

81% (34/42)

83% (104/126)

  1. C1-INH (SC) subcutaneous C1-inhibitor
Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us